|
Market Closed -
Nasdaq
16:00:00 2026-10-06 EDT
|
5-day change | 1st Jan Change | ||
| 222.89 USD | -0.31% |
|
-2.54% | +26.65% |
| 10-02 | Biogen's experimental lupus drug shows benefit against skin symptoms | RE |
| 10-02 | Biogen Says Litifilimab Shows Efficacy in New 52-Week Phase 2 Data | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| BIOGEN INC. | Biopharmaceuticals | -0.31% | -2.54% | +26.65% | +39.41% | -20.52% | 33.04B |  | | |
- Stock Market
- Stocks
- BIIB Stock
- Charts Biogen Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
